EDAP: Promoting the adoption of an innovative prostate cancer therapy
In January 2008, EDAP’s CEO Marc Oczachowski and CFO Eric Soyer were elated after raising $20million in capital from US investors. This cash infusion would fund the US-based clinical trials for EDAP’s revolutionary prostate cancer therapy. They were pivotal for EDAP to reach its goal of reaching US FDA approval, a fundamental condition for the company’s growth in the world’s largest prostate cancer market. But EDAP’s executives were fully aware of their shareholders’ pressure to see further growth and acceptance of HIFU’s (High Intensity Focused Ultrasound) as a “standard of care” therapy for non-invasive prostate cancer treatment in Europe. Within the past decade, EDAP had made significant progress in capturing the interest from the urological medical community and increasing the number of sites using its technology and of patients treated satisfactorily. However, market penetration for HIFU still faced specific issues: Its status as an experimental therapy, reluctance of urologists to adopt a new technology over surgery, competition from other technologies and treatment protocols, conservative attitudes from the health reimbursement agencies, and EDAP’s major resource constraints. Management was confronted with two types of challenges. In the short to medium term, the company needed to imagine innovative ways to accelerate the adoption of its technology in European and neighboring markets. This was necessary to reach profitability before the large US market would kick in and propel the company forward. In the longer term, EDAP had to determine the most desirable growth path beyond its current prostate cancer activities. Should the company define itself and try to grow as a urology company? As a HIFU cancer treatment specialist? Or more broadly as a therapeutic ultrasound specialist?
To examine and contemplate how a company gears their efforts to get a new medical technology embraced before it is a standard of care. The strategy is complex as gaining acceptance and use of an innovative medical technology requires the interest and adoption or multiple parties: the medical community, patients and the reimbursement agencies. Simultaneously, the company must manage and meet the expectations of their shareholders and keep the company’s efforts focused on growth and profitability.
2000-2008
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
Nespresso, the global leading brand in portioned coffee, is facing an existential threat. The company’s current market base, which consists primari...
By 2026, it's predicted that over 80% of organizations will have employed generative artificial intelligence (GenAI) in some capacity, up from less...
Choosing a CEO is a crucial decision for any company, but it becomes particularly complex in family businesses. This difficulty stems from the need...
Family businesses often have not only financial wealth but also nonfinancial values that make them different from nonfamily companies. For instance...
Leadership presence (LP) is widely acknowledged as a foundation of effective leadership. Historically, LP has been conceptualized as a collection o...
With organizations of all sorts facing increased urgency and unpredictability, being able to ask smart questions has become key. But unlike lawyers...
No company can grasp the potential of AI until it has set up a data-driven culture enabling employees to create value from the insights that emerge...
In a world where agility and global foresight are crucial for business survival and growth, the FUCHS case presents a compelling narrative of trans...
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in Harvard Business Review May-June 2024, vol. 102, issue 3
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications